Adis, a Wolters Kluwer Business, Auckland, New Zealand.
Drugs Aging. 2009;26(12):1049-71. doi: 10.2165/11203210-000000000-00000.
Bimatoprost (Lumigan) is a synthetic prostamide that reduces intraocular pressure (IOP) by increasing the outflow of aqueous humour. In patients with open-angle glaucoma or ocular hypertension, long-term treatment (for up to 48 months) with once-daily bimatoprost 0.03% ophthalmic solution was more effective than timolol twice daily in providing a sustained and stable reduction in IOP. Bimatoprost 0.03% ophthalmic solution demonstrated efficacy similar to, or greater than, the prostaglandin analogues latanoprost and travoprost in reducing IOP and achieving target IOP levels. Switching to bimatoprost was as effective in maintaining diurnal IOP control as switching to a fixed combination of latanoprost/timolol (in patients with IOP levels controlled with a nonfixed combination of latanoprost plus timolol), and similarly, or more, effective in lowering IOP and providing overall diurnal IOP control than switching to a combination of dorzolamide/timolol (in patients with IOP inadequately controlled with other antiglaucoma agents including timolol). Treatment with bimatoprost was generally well tolerated, with conjunctival hyperaemia (mostly mild), growth of eyelashes and ocular pruritus being commonly reported. Other adverse events included increases in the pigmentation of the iris, perorbital areas and eyelashes.
比马前列素（卢美根）是一种合成前列腺素类似物，通过增加房水流出降低眼内压（IOP）。在开角型青光眼或高眼压症患者中，每日一次应用 0.03%比马前列素滴眼液治疗长达 48 个月，在持续稳定降低 IOP 方面比每日两次应用噻吗洛尔更有效。0.03%比马前列素滴眼液在降低 IOP 和达到目标 IOP 水平方面的疗效与前列腺素类似物拉坦前列素和曲伏前列素相似，或优于后者。与转换为固定联合制剂（拉坦前列素/噻吗洛尔，在接受非固定联合制剂（拉坦前列素加噻吗洛尔）控制 IOP 的患者中）相比，转换为比马前列素同样有效或更有效（在接受包括噻吗洛尔在内的其他抗青光眼药物治疗眼压控制不佳的患者中），能更好地控制日间 IOP。比马前列素治疗一般耐受性良好，常见的不良反应有结膜充血（大多为轻度）、睫毛生长和眼痒。其他不良反应包括虹膜、眶周区域和睫毛色素沉着增加。
